Tuhura Biosciences, Inc. annual report, FY2022

Filing identity and reporting period

The supplied filing is Kintara Therapeutics, Inc.’s Form 10-K for the fiscal year ended June 30, 2022, filed September 27, 2022—not a Tuhura Biosciences, Inc. filing or a 2021 Q4 report. The summary below reflects the filing itself.

Business context

Kintara is a clinical-stage cancer therapeutics company with no product revenue to date. Its lead programs are VAL-083, being studied for glioblastoma (GBM), and REM-001 photodynamic therapy, being developed for cutaneous metastatic breast cancer (CMBC). The company relies on external financing and third parties for clinical development and manufacturing.

Financial performance and liquidity

At June 30, 2022, working capital was $9.3 million, total assets were $15.9 million, total liabilities were $4.2 million, and stockholders’ equity was $11.8 million. Cash provided by financing was $21.6 million, mainly from two registered direct offerings; cash increased by $1.2 million over the year. The company reported no investing cash flow in FY2022. The prior-year $0.5 million NBTS loan was repaid in June 2021; the filing reports no loan balance at FY2022 year-end.

No operating margins are meaningful because Kintara had no revenue. The filing reports an accumulated deficit of $136.4 million. It states that year-end cash, together with potential proceeds from the Lincoln Park facility, was expected to fund planned operations for less than one year from the filing date.

Changes versus the prior year

• R&D expense rose 28% to $15.2 million, mainly as the GBM AGILE study incurred a full year of ongoing costs and REM-001 manufacturing and study-preparation costs were incurred.
• G&A expense fell 23% to $7.5 million, primarily due to lower share-based compensation and professional fees.
• Net loss narrowed by $15.6 million, largely because FY2021 included a $16.1 million non-cash in-process R&D charge related to the Adgero merger. Despite the lower accounting loss, operating cash use increased by $1.5 million.
• FY2022 financing included approximately $21.6 million net proceeds from offerings. These transactions issued common shares and warrants; subsequent exercises or conversions may dilute existing holders.

Outlook, risks and unusual items

• Going concern: The auditor’s report includes an explanatory paragraph stating that substantial doubt exists about Kintara’s ability to continue as a going concern. Management said additional financing is required; planned equity, debt, partnership, or Lincoln Park proceeds are uncertain and do not remove that doubt.
• Clinical outlook: Management targeted REM-001’s first patient in a 15-patient CMBC study around late Q3 2022 and topline results around late Q3 2023. It targeted VAL-083 topline results from the GBM AGILE study around late Q4 2023. These are plans, not assured outcomes. The FDA granted VAL-083 Fast Track Designation for newly diagnosed unmethylated GBM in June 2022 and issued a Study May Proceed letter for the REM-001 study in August 2022.
• Clinical evidence and safety: VAL-083 results cited in the filing are from prior studies and are not head-to-head comparisons with historical controls. Myelosuppression was a key VAL-083 adverse event. Prior REM-001 studies reported treatment-related pain and photosensitivity, as well as serious adverse events; the company’s CMBC efficacy analysis uses legacy study data that FDA may not accept as sufficient for approval.
• Funding and dilution: The August 2022 Lincoln Park agreement allows up to $20 million of purchases subject to conditions and share limits; it is not guaranteed funding. Kintara reported approximately $1.976 million of gross proceeds from shares sold under the facility after year-end. Preferred-stock dividends, warrants, options, and additional equity issuance also present dilution risks.
• Other risks and obligations: COVID-related contract manufacturing delays could affect REM-001 timing. The filing reports $14.9 million of clinical development and manufacturing commitments, plus contingent REM-001 milestone payments of $0.3 million and $0.7 million and a 6% royalty on applicable net sales under the St. Cloud agreement. Nasdaq had extended the deadline to regain its $1.00 minimum bid-price compliance to November 28, 2022; delisting remained a risk.
• Audit and controls: Marcum LLP gave an unqualified opinion on the financial statements, with the going-concern explanatory paragraph. Management reported effective disclosure controls and internal control over financial reporting as of June 30, 2022; the auditor was not engaged to opine on internal-control effectiveness.

Important facts for investors to verify

• Confirm the issuer and reporting period: this filing is Kintara Therapeutics’ FY2022 10-K, notwithstanding the request metadata.
• Review the going-concern disclosure, cash runway assumptions, actual subsequent Lincoln Park proceeds, and any financing or partnership developments.
• Track GBM AGILE enrollment and results, REM-001 study initiation and enrollment, and whether stated milestone dates have changed.
• Assess the FDA’s view of REM-001’s legacy data, the planned study design, manufacturing readiness, and the risks and adverse events disclosed for both programs.
• Evaluate dilution from common warrants, preferred stock and its stock dividends, stock options, and the Lincoln Park equity facility.
• Check Nasdaq bid-price compliance status and the company’s clinical commitments, contingent milestone obligations, and royalty arrangements.